Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma
Yıl: 2022 Cilt: 2 Sayı: 4 Sayfa Aralığı: 29 - 34 Metin Dili: İngilizce DOI: 10.14744/eer.2022.19484 İndeks Tarihi: 25-05-2023
Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma
Öz: Purpose: The purpose of this study was to evaluate the treatment results and complications of XEN-45 microstent implan- tation in open-angle glaucoma. Methods: In this study, 17 eyes of 17 patients who underwent XEN-45 implantation with 0.2 mg/cc mitomycin-c between June 2016 and February 2018 were retrospectively examined. Pre- and post-operative best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of antiglaucomatous drugs, endothelial cell count (ECC), retinal nerve fiber layer (RNFL) thickness, number of post-operative needlings, and post-operative complications were evaluated. Results: The mean age of the patients (11 M, 6 F) was 62.6±19.8 (29–94) years and mean follow-up period was 16.8±3.5 (12–21) months. The mean IOP which was 27.6±6.0 (21–40) mmHg before glaucoma surgery decreased significantly to 14.1±3.3 3.4 (8–20) mmHg at the last visit (p<0.001). The number of antiglaucomatous drugs was 3.9±0.8 (2–5) preopera- tively and 1.7±1.3 (0–3) at the final examination (p=0.001). Pre-operative BCVA was 0.78±0.99 LogMAR and 0.8±0.99 LogMAR at the last visit (Wilcoxon test, p=0.99). The ECC was 2356.8±533.3 (1635–3275) cells/mm2 preoperatively and 2338.7±472.7 (1712–3178) cells/mm2 at the last visit and did not show statistically significant difference (p=0.470). The pre- and post-op- erative RNFL thickness measurements were 61.4±11.8 (43–82) μm and 61.3±11.5 (45–82) μm at the last visit, respectively (p=0.764). Needling was required in 4 (23.5%) eyes. Post-operative complications were observed in four eyes (23.5%). In the early post-operative period (≤1 month), shallow anterior chamber and hypotony were detected in 1 eye and were treated medically. As late complications (>1 month), Tenon’s cyst in two eyes and fibrotic bleb in one eye were observed. Conclusion: XEN-45 implant surgery in open-angle glaucoma patients is an effective surgical procedure for IOP control. With preserved visual acuity and ECC, causing no devastating complications, it can also be considered as a very safe option in open-angle glaucoma cases.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- World Health Organization(WHO). Bulletin of the World Health Organization Past issues. Vol. 82. Geneva: World Health Orga- nization; 2004. p. 814–90. Available from: https://www.who. int/bulletin/volumes/82/11/feature1104/en; https://www. ncbi.nlm.nih.gov/pmc/issues/175448. Accessed Nov 30, 2022.
- Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Oph- thalmology 2014;121:2081–90.
- Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hus- sein M, et al. Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268–79.
- Ansari E. An update on implants for minimally invasive glaucoma surgery (MIGS), Ophthalmol Ther 2017;6:233–41.
- Saheb H, Ahmed IIK. Micro-invasive glaucoma surgery: Current perspectives and future directions. Curr Opin Ophthal- mol 2012;23:96–104.
- Sheybani A, Dick HB, Ahmed II. Early clinical results of a novel Ab interno gel stent for the surgical treatment of open-angle glaucoma. J Glaucoma 2016;25:e691–6.
- Galal A, Bilgic A, Eltanamly R, Osman A. XEN glaucoma implant with mitomycin C 1-year follow-up: Result and complications. J Ophthalmology 2017;2017:5457246.
- Sheybani A, Lenzhofer M, Hohensinn M, Reitsamer H, Ahmed II. Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: Pilot study. J Cataract Re- fract Surg 2015;41:1905–9.
- Sheybani A, Ahmed IK. Ab İnterno Gelatin Stent with Mito- mycin-C Combined with Cataract Surgery for Treatment of Open-angle Glaucoma: 1-year Results. Presented at ASCRS; 2015.
- Grover S, Gomez I, Reitsamer H, Sheybani A. Development of Minimally İnvaziv Collagen Stent for Treating Glaucoma: First 975 Eyes Treated. ASCRS Symposium and Congress; 2016.
- Sng CC, Wang J, Hau S, Htoon HM, Barton K. XEN-45 collagen implant for the treatment of uveitic glaucoma. Clin Exp Ophtalmol 2018;46:339–45.
- Mansouri K, Guidotti J, Rao HL, Oubas A, D’Alessandro E, Roy S, et al. Prospective evaluation of standalone XEN gen implant and combined phacoemulsification-XEN gel implant surgery: 1-year results. J Glaucoma 2018;27:140–7.
- Lim SY, Betzler BK, Yip LW, Dorairaj S, Ang BC. Standalone XEN45 gel stent implantation in the treatment of open-angle glaucoma: A systematic review and meta-analysis. Surv Oph- thalmol 2022;67:1048–61.
- Olate-Perez A, Perez-Torregrosa VT, Gargallo-Benedicto A, Neira-Ibáñez P, Cerdà-Ibáñez M, Osorio-Alayo V, et al. Prospec- tive study of filtering blebs after XEN45 surgery. Arch Soc Esp Oftalmol 2017;92:366–71.
- Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Combined and stand-alone XEN 45 gel stent implantation: 3-year outcomes and success predictors. Acta Ophthalmol 2021;99:e531-9.
- Eraslan M, Ozcan AA, Dericioglu V, Ciloglu E. Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients. Int Ophthalmol 2021;41:3371–9.
- Oddone F, Roberti G, Posarelli C, Agnifili L, Mastropasqua L, Carnevale C, et al. Endothelial cell density after XEN implant surgery: Short-term data from the Italian XEN glaucoma treat- ment registry (XEN-GTR). J Glaucoma 2021;30:559–65.
- Olgun A, Duzgun E, Yildiz AM, Atmaca F, Yildiz AA, Sendul SY. XEN gel stent versus trabeculectomy: Short-term effects on corneal endothelial cells. Eur J Ophthalmol 2021;31:346–53.
| APA | Erbey M, Esen Baris M, Ateş H, Guven Yılmaz S (2022). Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. , 29 - 34. 10.14744/eer.2022.19484 |
| Chicago | Erbey Meryem,Esen Baris Mine,Ateş Halil,Guven Yılmaz Suzan Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. (2022): 29 - 34. 10.14744/eer.2022.19484 |
| MLA | Erbey Meryem,Esen Baris Mine,Ateş Halil,Guven Yılmaz Suzan Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. , 2022, ss.29 - 34. 10.14744/eer.2022.19484 |
| AMA | Erbey M,Esen Baris M,Ateş H,Guven Yılmaz S Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. . 2022; 29 - 34. 10.14744/eer.2022.19484 |
| Vancouver | Erbey M,Esen Baris M,Ateş H,Guven Yılmaz S Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. . 2022; 29 - 34. 10.14744/eer.2022.19484 |
| IEEE | Erbey M,Esen Baris M,Ateş H,Guven Yılmaz S "Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma." , ss.29 - 34, 2022. 10.14744/eer.2022.19484 |
| ISNAD | Erbey, Meryem vd. "Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma". (2022), 29-34. https://doi.org/10.14744/eer.2022.19484 |
| APA | Erbey M, Esen Baris M, Ateş H, Guven Yılmaz S (2022). Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. European eye research, 2(4), 29 - 34. 10.14744/eer.2022.19484 |
| Chicago | Erbey Meryem,Esen Baris Mine,Ateş Halil,Guven Yılmaz Suzan Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. European eye research 2, no.4 (2022): 29 - 34. 10.14744/eer.2022.19484 |
| MLA | Erbey Meryem,Esen Baris Mine,Ateş Halil,Guven Yılmaz Suzan Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. European eye research, vol.2, no.4, 2022, ss.29 - 34. 10.14744/eer.2022.19484 |
| AMA | Erbey M,Esen Baris M,Ateş H,Guven Yılmaz S Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. European eye research. 2022; 2(4): 29 - 34. 10.14744/eer.2022.19484 |
| Vancouver | Erbey M,Esen Baris M,Ateş H,Guven Yılmaz S Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma. European eye research. 2022; 2(4): 29 - 34. 10.14744/eer.2022.19484 |
| IEEE | Erbey M,Esen Baris M,Ateş H,Guven Yılmaz S "Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma." European eye research, 2, ss.29 - 34, 2022. 10.14744/eer.2022.19484 |
| ISNAD | Erbey, Meryem vd. "Treatment results of standalone XEN-45 implantation in patients with primary and secondary open-angle glaucoma". European eye research 2/4 (2022), 29-34. https://doi.org/10.14744/eer.2022.19484 |
